Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,596.80INR
18 Jan 2019
Change (% chg)

Rs-22.35 (-0.85%)
Prev Close
Rs2,619.15
Open
Rs2,605.00
Day's High
Rs2,629.35
Day's Low
Rs2,594.50
Volume
536,273
Avg. Vol
853,182
52-wk High
Rs2,749.95
52-wk Low
Rs1,887.00

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs394,104.81
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.84

Financials

  REDY.NS Industry Sector
P/E (TTM): 32.79 30.48 33.71
EPS (TTM): 72.46 -- --
ROI: -- 14.98 14.48
ROE: -- 16.31 15.99

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

18 Dec 2018

UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival

* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)

01 Nov 2018

UPDATE 1-Indian drugmaker Dr. Reddy's Q2 profit soars past market estimates

Oct 26 Dr.Reddy's Laboratories posted a better-than-expected rise in second-quarter profit as higher sales in some emerging countries offset a marginal decline in business in North America, a key market for the Indian generic drugmaker.

26 Oct 2018

Indivior - U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

31 Jul 2018

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

31 Jul 2018

UPDATE 1-Indivior: U.S. court rules against generic rival's appeal

July 31 Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

31 Jul 2018

Morning News Call - India, July 27

To access the newsletter, click on the link: http://share.thomsonreuters.com/assets/newsletters/Indiamorning/MNC_IN_07272018.pdf If you would like to receive this newsletter via email, please register at: https://forms.thomsonreuters.com/india-morning/ FACTORS TO WATCH 9:30 am: IBA Banking HR Conclave in Mumbai. 10:30 am: NITI Aayog CEO Amitabh Kant at an event in New Delhi. LIVECHAT - G7 FX CHARTING Wilson Leung, chief market strategist at Trendsetter

27 Jul 2018

India's Dr.Reddy's profit soars on anti-opioid drug sales in U.S.

Indian generic drugmaker Dr.Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.

26 Jul 2018

UPDATE 1-India's Dr.Reddy's profit soars on anti-opioid drug sales in U.S.

July 26 Indian generic drugmaker Dr.Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the U.S. launch of a generic version of an opioid addiction drug.

26 Jul 2018

India's Dr. Reddy's Q1 net profit rises seven-fold, beats forecast

July 26 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted an over seven-fold rise in first-quarter net profit on Thursday, handily beating market expectations, aided by the launch of a generic version of an opioid addiction drug.

26 Jul 2018

Earnings vs. Estimates